Dr. Stevenson on Potential of Immunotherapy in Squamous NSCLC

James Stevenson, MD
Published: Thursday, Sep 08, 2016


James Stevenson, MD, medical oncologist at Cleveland Clinic, discusses the potential of immunotherapy agents as treatment for patients with squamous non–small cell lung cancer (NSCLC).

Stevenson predicts that the landscape of squamous NSCLC will be completely different in the coming years, especially in the frontline setting. Here, immunotherapy may more often be a first choice by oncologists compared with chemotherapy. Additionally, combination therapies with chemotherapy plus monoclonal antibodies, such as necitumumab (Portrazza), will also likely be given as a later-line treatment for patients.

Further research will help oncologists decide on the first-, second-, and third-line regimens for squamous NSCLC, as well as their own clinical experience, Stevenson adds.
SELECTED
LANGUAGE

James Stevenson, MD, medical oncologist at Cleveland Clinic, discusses the potential of immunotherapy agents as treatment for patients with squamous non–small cell lung cancer (NSCLC).

Stevenson predicts that the landscape of squamous NSCLC will be completely different in the coming years, especially in the frontline setting. Here, immunotherapy may more often be a first choice by oncologists compared with chemotherapy. Additionally, combination therapies with chemotherapy plus monoclonal antibodies, such as necitumumab (Portrazza), will also likely be given as a later-line treatment for patients.

Further research will help oncologists decide on the first-, second-, and third-line regimens for squamous NSCLC, as well as their own clinical experience, Stevenson adds.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Year in Review™: Reflecting on Recent Evidence With an Eye to the Future of Lung Cancer ManagementMar 30, 20191.5
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x